scholarly journals Antiviral activity of Pacific oyster (Crassostrea gigas) hemolymph against a human coronavirus.

2021 ◽  
Author(s):  
Rebecca L Pedler ◽  
James Harris ◽  
Peter G Speck
Keyword(s):  
Antiviral Activity ◽  
Crassostrea Gigas ◽  
Pacific Oyster ◽  
Respiratory Infections ◽  
Human Coronavirus ◽  
Fold Reduction ◽  
Intracellular Stage

Coronaviruses can can cause severe respiratory infections in humans. This study aimed to assess the antiviral activity of Pacific oyster (Crassostrea gigas) hemolymph against a human coronavirus, HCoV-229E. An eight-fold reduction in infectivity of HCoV-229E on Huh-7 cells was observed in the presence of 10% C. gigas hemolymph. Antiviral activity of C. gigas hemolymph positively correlated with its concentration and appears to be active during an intracellular stage of HCoV-229E infection.

Evidence that the major hemolymph protein of the Pacific oyster, Crassostrea gigas, has antiviral activity against herpesviruses

2014 ◽  
Vol 110 ◽  
pp. 168-174 ◽  
Author(s):  
Timothy J. Green ◽  
Nick Robinson ◽  
Tim Chataway ◽  
Kirsten Benkendorff ◽  
Wayne O’Connor ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Crassostrea Gigas ◽  
Pacific Oyster ◽  
The Pacific ◽  
Hemolymph Protein

scholarly journals Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Michael G. Sugiyama ◽  
Haotian Cui ◽  
Dar’ya S. Redka ◽  
Mehran Karimzadeh ◽  
Edurne Rujas ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Drug Targets ◽  
Respiratory Infections ◽  
Antiviral Drug ◽  
Drug Repurposing ◽  
Human Coronavirus ◽  
Independent Manner ◽  
Convolutional Networks ◽  
Target Drug ◽  
Coronavirus Infection

AbstractThe COVID-19 pandemic has highlighted the urgent need for the identification of new antiviral drug therapies for a variety of diseases. COVID-19 is caused by infection with the human coronavirus SARS-CoV-2, while other related human coronaviruses cause diseases ranging from severe respiratory infections to the common cold. We developed a computational approach to identify new antiviral drug targets and repurpose clinically-relevant drug compounds for the treatment of a range of human coronavirus diseases. Our approach is based on graph convolutional networks (GCN) and involves multiscale host-virus interactome analysis coupled to off-target drug predictions. Cell-based experimental assessment reveals several clinically-relevant drug repurposing candidates predicted by the in silico analyses to have antiviral activity against human coronavirus infection. In particular, we identify the MET inhibitor capmatinib as having potent and broad antiviral activity against several coronaviruses in a MET-independent manner, as well as novel roles for host cell proteins such as IRAK1/4 in supporting human coronavirus infection, which can inform further drug discovery studies.

Sign in / Sign up

Export Citation Format

Share Document